TNF-α inhibitor users had less open-angle glaucoma over 10 years

Design

Retrospective propensity-matched multicentre records cohort

Population

11,915 matched pairs of adults ≥40, TNF-α inhibitor users vs controls

Primary outcome

New primary open-angle glaucoma diagnosis within 10 years

Effect

2.0% vs 3.3%; HR 0.70 (0.59–0.82)

Using pooled electronic health records from 70 US healthcare organisations, this study matched 11,915 adults aged 40 or over taking a systemic TNF-α inhibitor with controls who had the same underlying indications but no TNF-α inhibitor exposure. People with uveitis were excluded.

At 10 years, a new diagnosis of primary open-angle glaucoma was recorded in 2.0% of TNF-α inhibitor users against 3.3% of controls (HR 0.70, 95% CI 0.59–0.82). Adalimumab and infliximab users each showed lower risk; there were no significant differences between agents.

This supports the idea that inflammation contributes to glaucomatous neurodegeneration, but it is a coded-diagnosis association. People on biologics may be examined differently, and residual confounding is likely. It is a research signal, not a reason to change glaucoma or rheumatology treatment.

• Do not alter glaucoma screening or treatment based on a patient's TNF-α inhibitor use.
• Keep routine glaucoma screening for patients over 40 on biologics as for anyone else.
• The finding supports inflammation as a research target in glaucoma.
• Diagnoses came from billing codes, which may misclassify glaucoma suspects.

Why it matters

It adds weight to inflammation as a modifiable pathway in a disease treated almost entirely through pressure.

Don't overread it

Observational, using coded diagnoses; it cannot show that TNF-α inhibitors prevent glaucoma.

The statistics, in plain English

An HR of 0.70 means about 30% lower hazard of a glaucoma diagnosis. In absolute terms the difference was 1.3 percentage points over 10 years.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.